DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: ADVAIR DISKUS 100/50
Summary for Tradename: ADVAIR DISKUS 100/50
|
|
Latest news for ADVAIRFor Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is ...20 May 2013, 10:56 am Why Did This Biotech Soar?13 May 2013, 2:06 pm FDA approves Glaxo/Theravance drug for COPD lung disease10 May 2013, 1:33 pm FDA OKs GlaxoSmithKline Drug to Treat Lung Disease10 May 2013, 12:25 pm FDA approves once-a-day inhaler from Glaxo10 May 2013, 11:47 am Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu6 May 2013, 8:59 am Research and Markets: Inhalation & Nasal Spray Generic Drugs 20122 May 2013, 5:41 pm Buy These Patent-Cliff Proof Stocks29 April 2013, 10:27 am AstraZeneca First-Quarter Sales Fell 13% on Generics25 April 2013, 2:32 am Courtesy of Yahoo News | ||||||||
Clinical Trials for: ADVAIR DISKUS 100/50Fall Epidemic Viral Pediatric Study Status: Completed Condition: Asthma A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS Status: Completed Condition: Asthma The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD Status: Withdrawn Condition: Chronic Obstructive Pulmonary Disease; Sleep Disorders Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Status: Recruiting Condition: Asthma The Effect on Depressive Symptoms in ECF Residents With COPD Status: Completed Condition: Chronic Obstructive Pulmonary Disease; Depression Atlantis Symbicort Status: Completed Condition: Asthma 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old Status: Recruiting Condition: Asthma Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation Status: Completed Condition: Chronic Obstructive Pulmonary Disease (COPD) Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Status: Not yet recruiting Condition: COPD Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects Status: Recruiting Condition: Asthma Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ADVAIR DISKUS 100/50 | fluticasone propionate; salmeterol xinafoate | POWDER; INHALATION | 021077 | Aug 24, 2000 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glaxosmithkline | ADVAIR DISKUS 100/50 | fluticasone propionate; salmeterol xinafoate | POWDER; INHALATION | 021077 | Aug 24, 2000 | RX | Yes | 4,992,474*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glaxosmithkline | ADVAIR DISKUS 100/50 | fluticasone propionate; salmeterol xinafoate | POWDER; INHALATION | 021077 | Aug 24, 2000 | RX | Yes | 5,126,375*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glaxosmithkline | ADVAIR DISKUS 100/50 | fluticasone propionate; salmeterol xinafoate | POWDER; INHALATION | 021077 | Aug 24, 2000 | RX | Yes | 5,225,445*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc